Production (Stage)
REGENXBIO Inc.
RGNX
$10.35
$1.5016.95%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 469.79% | -4.50% | -16.31% | 11.60% | -18.37% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 469.79% | -4.50% | -16.31% | 11.60% | -18.37% |
| Cost of Revenue | -4.40% | 8.18% | -5.32% | 2.23% | -5.59% |
| Gross Profit | 174.68% | -7.74% | -2.31% | 39.45% | -0.03% |
| SG&A Expenses | 11.24% | -18.11% | -15.86% | -20.44% | -19.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 144.12% | 605.93% | -83.18% | 11.54% | -203.03% |
| Total Operating Expenses | -0.64% | -11.93% | -8.09% | -15.85% | -9.27% |
| Operating Income | 119.64% | 14.68% | 4.44% | 23.35% | 6.64% |
| Income Before Tax | 109.61% | 18.81% | 3.67% | 26.47% | 5.02% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 109.61% | 18.61% | 3.67% | 26.47% | 5.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 109.61% | 18.61% | 3.67% | 26.47% | 5.02% |
| EBIT | 119.64% | 14.68% | 4.44% | 23.35% | 6.64% |
| EBITDA | 127.93% | 15.26% | 4.08% | 24.30% | 7.09% |
| EPS Basic | 108.55% | 29.60% | 16.67% | 36.74% | 9.76% |
| Normalized Basic EPS | 108.84% | 25.39% | 16.67% | 36.74% | 12.75% |
| EPS Diluted | 108.55% | 29.60% | 16.79% | 36.75% | 9.76% |
| Normalized Diluted EPS | 108.83% | 25.39% | 16.67% | 36.74% | 12.75% |
| Average Basic Shares Outstanding | 12.31% | 15.61% | 15.60% | 16.24% | 5.25% |
| Average Diluted Shares Outstanding | 12.47% | 15.61% | 15.60% | 16.24% | 5.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |